TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03202212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mixed on-line hemodiafiltration
Description: This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High flux bicarbonate dialysis
Description: Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
Study: NCT03396627

Intervention type: DIAGNOSTIC_TEST
Intervention: pathological examination
Description: fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
Study: NCT03579069

Intervention type: OTHER
Intervention: Ductus venosus Doppler
Description: Ductus venosus Doppler
Study: NCT02959788

Intervention type: OTHER
Intervention: Heart rate variability
Description: All patients have a 10-minute recording analyzed for indices of heart rate variability.
Study: NCT03215498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
Study: NCT01103440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel
Description: IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally

Intervention type: DRUG
Group type: OTHER
Intervention: Antiplatelet Therapy (ASA, Clopidogrel)
Description: Standard antiplatelet PCI treatment
Study: NCT03800277

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry
Description: Supplementation of polyphenols from cranberry extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry
Description: Supplementation of polyphenols from cranberry extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaves
Description: Supplementation of inulin from Agaves powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaves
Description: Supplementation of inulin from Agaves powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Supplementation with placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Supplementation with placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation with placebo
Study: NCT01466205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAR-0100A
Description: DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
Study: NCT00570713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Monoclonal antibody administered once weekly by intravenous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: As per package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
Study: NCT02625220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype toric lens senofilcon A
Description: Investigational prototype
Study: NCT03160456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
Study: NCT00650663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: oral tablet; simvastatin 20 mg once daily for 12 weeks
Study: NCT01799343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersion into water
Description: Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
Study: NCT00525434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraffix LTB
Description: wounds closure by using laser and albumin
Study: NCT02954458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TED
Description: 0.05 mg/kg SC injection once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard safety assessments and adjustments in nutritional support.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: Teduglutide will be administered using syringe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Teduglutide will be administered using needle.
Study: NCT02357199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive oral care & didactic training
Description: Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
Study: NCT02092727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Interventions for Dialysis Facilities
Description: 1. Educational seminars and monthly educational webinars~2. Peer-to-peer mentoring program~3. Bulletin boards about transplantation~4. Facility-specific feedback reports detailing transplant referral data for their center compared to state average~5. Formulate a facility-specific improvement plan to increase transplant referrals.~6. Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~7. Monthly monitoring and reporting of patient referrals to ESRD Network~8. Conduct a patient and family education session about transplantation~9. Host a movie day to show Living ACTS (About Choices in Transplantation \& Sharing) video
Study: NCT04233528

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of systemic skin microvascular endothelial function
Description: Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of systemic skin microvascular endothelial function
Description: Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
Study: NCT01152697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: haloperidol decanoate
Description: Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: haloperidol
Description: Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement
Description: CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
Study: NCT04528108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine
Description: Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gong Xue Ning capsules
Description: Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
Study: NCT04038684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Weight Control (MBWC)
Description: Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Control (SBWC)
Description: Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
Study: NCT04600128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dairy-based greek yogurt
Description: Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dairy-based cheddar cheese
Description: Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based yogurt
Description: Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based cheese
Description: Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
Study: NCT04427566

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
Study: NCT00496808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin (Trastuzumab)
Description: 8 mg/kg IV Over 90 Minutes
Study: NCT01721655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
Study: NCT04233528

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of systemic skin microvascular endothelial function
Description: Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
Study: NCT01119144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polycaprolactone / Tri-Calcium Phosphate
Description: Orbital implant for reconstruction of the orbital walls

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Mesh
Description: Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
Study: NCT01721655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
Study: NCT01256801

Intervention type: BIOLOGICAL
Intervention: cytokine
Description: interleukin 2 2 million unit every week
Study: NCT00345839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
Study: NCT02117752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel vehicle
Description: Patches containing dapsone gel vehicle will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel vehicle
Description: Patches containing dapsone gel vehicle will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium lauryl sulfate
Description: Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Patches containing normal saline (Negative Control) will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Patches containing normal saline (Negative Control) will be applied to the skin.
Study: NCT02652689

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diagnostic ultrasound radiation
Description: Recording Doppler ultrasound signals from the right chest wall
Study: NCT04541303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: tranexamic acid diluted to concentration of 25ml/mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.9% sodium chloride
Study: NCT00798642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: 8 weeks of gut-directed hypnotherapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: 8 weeks of standard of care

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mind Body Therapy
Description: 8 weeks of mind-body therapy
Study: NCT03282526

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body plethysmography
Description: Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
Study: NCT00805922

Intervention type: OTHER
Intervention: No treatment given
Description: Capillary or venous blood will be drawn for analysing HbA1c.
Study: NCT02165345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly
Study: NCT03412500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin equation-based method
Description: Vancomycin dosage will be adjusted according to the equation-based method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin trough concentration method
Description: Vancomycin dosage will be adjusted according to the trough concentration method
Study: NCT00901381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 µg/kg subcutaneously once daily x 5 days
Study: NCT01664819

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02320630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entanercept
Description: Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entanercept
Description: Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
Study: NCT03230799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional cataract surgery
Description: ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
Study: NCT02327117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01816919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collecting breath samples
Study: NCT02320630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entanercept
Description: Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
Study: NCT02000661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Description: Fractional Flow Reserve (FFR) performed per guidelines to guide PCI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve (FFR)
Description: Fractional Flow Reserve (FFR) performed per guidelines to guide PCI